|
Charles J. Bramlage joined Valeant Pharmaceuticals as President, Europe in September 2003. Mr. Bramlage is responsible for Valeant's Western, Central and Eastern European markets. Mr. Bramlage has more than 20 years of pharmaceutical experience with a strong background in marketing and sales. Prior to joining Valeant, Mr. Bramlage was President and Chief Executive Officer of BattellePharma, Inc., a specialty pharmaceutical company developing products using new inhalation technology.
Before joining BattellePharma in 2001, Mr. Bramlage was Vice President of Respiratory Global Commercial Development and Vice President of U.S. Respiratory and Cardiovascular Marketing for GlaxoSmithKline. He was responsible for the global launch of Seretide�/Advair� and the U.S. launch of Flovent�, drove the new respiratory global strategy for Seretide/Advair and led the team that catapulted Serevent�, Flovent and Flonase� to the top position in the U.S. market. Mr. Bramlage has been involved in marketing pharmaceuticals at two market-leading organizations (Merck and GlaxoSmithKline) in eight different therapeutic areas: infectious disease, cardiovascular, pain, digestive disorders, vaccines, oncology, central nervous system, and respiratory. Mr. Bramlage has served as an integral factor in the commercialization of 22 brands, including major names such as Zantac�, Fortaz�, Pepcid�, Prinivil�, Imitrex�, Zofran�, Navelbine�, as well as the above-mentioned respiratory brands.
Mr. Bramlage received a Bachelor of Science degree in Marketing from The Ohio State University and earned a Master in Business Administration from the University of Dayton. | 